Figure 3. Individual-patient level data meta-analytic HRs for the effect of any irAE, dermatologic, hepatitis, thyroid, pneumonitis and colitis irAEs on overall survival in patients treated with atezolizumab (mono or in combination) and with chemotherapy. TRT: C=chemotherapy, chemotherapy regimen or chemotherapy with bevacizumab; TRT: C-IO=treatment with atezolizumab in combination with chemotherapy or bevacizumab; FDR, false discovery rate; hepatitis, immune-related hepatitis (clinical diagnosis), immune-related hepatitis (laboratory abnormalities); TRT: IO= treatment with atezolizumab monotherapy; irAEs, immune-related adverse events were reported in all study arms, including standard of care without atezolizumab, given the blinded nature of the controlled trials; skin, immune-related rash, immune-related severe cutaneous reactions; thyroid, immune-related hypothyroidism, immune-related hyperthyroidism, immune-related thyroiditis.